A platform for next-generation pharmaceutical products.
A proprietary biphasic drug delivery platform engineered to optimize pharmacokinetics, enable differentiated combination therapies, and unlock new value around established molecules.
Traditional drug delivery vs. the biphasic platform.
Short half-life pharmaceuticals are commercially constrained by single-peak exposure profiles. The biphasic platform engineers a second, programmed release phase to extend therapeutic coverage from a single oral dose.
One dose. Two engineered peaks. Sustained 24-hour coverage.
- Rapid Peak
- Rapid Decline
- Sub-Therapeutic Trough
- Immediate Release Phase
- First Therapeutic Exposure
- Delayed Release Phase
- Second Therapeutic Exposure
- Extended Coverage
Traditional Drug
- Rapid Peak
- Rapid Decline
- Sub-Therapeutic Trough
- Multi-Dose Regimens Required
Biphasic Drug Delivery
- Immediate Release
- Therapeutic Exposure
- Delayed Release
- Second Exposure Phase
- Extended Daily Coverage
Combination Immediate / Delayed Release Delivery System for Short Half-Life Pharmaceuticals.
A Platform Technology, Not A Single Product.
The value of the patent lies in its ability to support the development of multiple differentiated pharmaceutical products across numerous therapeutic categories.
Platform™
Broad Pharmaceutical Applicability.
The patented technology was originally developed using Biphasic / Combo as an example application. However, the intellectual property is fundamentally a delivery platform designed to improve the pharmacokinetic performance of drugs characterized by short half-lives, limited absorption windows, or dosing regimens that may benefit from dual-phase release.
The commercial opportunity extends far beyond any single drug.
- Small molecule therapeutics
- Pharmaceutical salts and prodrugs
- SGLT2 inhibitors
- GLP-1-based therapies exploring oral delivery strategies
- Combination metabolic therapies
- Drugs requiring optimized exposure profiles
- Existing branded products approaching patent expiration
- Generic molecules seeking differentiation
Potential Applications Across Modern Therapeutics.
Search across therapeutic areas, filter by strategic priority, and select a category to reveal example applications connected back to the Biphasic Drug Delivery Platform.
Metabolic Disease
- SGLT2 Inhibitors
- Metformin Combinations
- Combination Diabetes Therapies
- Obesity Treatments
- Metabolic Syndrome
Positioned as a platform technology, not a single-product asset.
Ideal Partner Applications.
The platform may allow pharmaceutical companies to create differentiated products around existing molecules while potentially improving convenience, optimizing pharmacokinetics, and creating new commercial opportunities.
Designed For The Next Generation Of Combination Therapies.
The platform may support the development of combination therapies where multiple agents are commonly prescribed together — delivering each component on its optimal release schedule from a single dosage form.
A platform aligned with the largest commercial opportunities in pharma.
Pharmaceutical companies continually seek technologies that improve patient convenience, product differentiation, adherence, and commercial value. Innovative delivery systems represent substantial strategic value across multiple therapeutic categories.
Seeking strategic development and licensing partners.
We are looking for partners who want to build differentiated products using this platform.
Flexible deal structures
One platform. Multiple molecules. Compounding value.
View investor thesisProprietary Platform Patent
US Patent 10,940,159 B2 — composition and method-of-use protection.
Drug Delivery Innovation
A platform addressing short half-life pharmaceutical challenges.
Licensing Optionality
Multi-asset, multi-territory licensing optionality across one platform.
Global Pharmaceutical Markets
Exposure to expanding therapeutic categories worldwide.
Recurring Royalty Potential
Optionality across milestones, royalties, and platform transactions.
Scalable Monetization
Same platform, repeatable transactions across multiple molecules.
Build a differentiated product on the biphasic platform.
Whether you represent a pharmaceutical developer, a value-added generic company, specialty pharma, a global pharmaceutical, or a strategic investor — we welcome conversations regarding licensing, partnership, and platform access.